Hunan Er-Kang Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Hunan Er-Kang Pharmaceutical has a total shareholder equity of CN¥4.7B and total debt of CN¥399.4M, which brings its debt-to-equity ratio to 8.5%. Its total assets and total liabilities are CN¥5.4B and CN¥695.7M respectively.
Key information
8.5%
Debt to equity ratio
CN¥399.39m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥768.37m |
| Equity | CN¥4.70b |
| Total liabilities | CN¥695.74m |
| Total assets | CN¥5.39b |
Recent financial health updates
Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
Sep 26
Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?
Jun 03Recent updates
Subdued Growth No Barrier To Hunan Er-Kang Pharmaceutical Co., Ltd (SZSE:300267) With Shares Advancing 27%
Sep 30Hunan Er-Kang Pharmaceutical (SZSE:300267) Has Debt But No Earnings; Should You Worry?
Sep 26What Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) 28% Share Price Gain Is Not Telling You
Aug 08Health Check: How Prudently Does Hunan Er-Kang Pharmaceutical (SZSE:300267) Use Debt?
Jun 03Pinning Down Hunan Er-Kang Pharmaceutical Co., Ltd's (SZSE:300267) P/S Is Difficult Right Now
Mar 27Financial Position Analysis
Short Term Liabilities: 300267's short term assets (CN¥1.7B) exceed its short term liabilities (CN¥626.9M).
Long Term Liabilities: 300267's short term assets (CN¥1.7B) exceed its long term liabilities (CN¥68.8M).
Debt to Equity History and Analysis
Debt Level: 300267 has more cash than its total debt.
Reducing Debt: 300267's debt to equity ratio has increased from 0% to 8.5% over the past 5 years.
Debt Coverage: 300267's debt is well covered by operating cash flow (61.8%).
Interest Coverage: Insufficient data to determine if 300267's interest payments on its debt are well covered by EBIT.